Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

S.H.I. Ou; S.M. Gadgeel; F. Barlesi; J.C.H. Yang; L. De Petris; D.W. Kim; R. Govindan; A.M. Dingemans; L. Crino; H. Lena; S. Popat; J.S. Ahn; E. Dansin; E. Mitry; B. Muller; W. Bordogna; B. Balas; P.N. Morcos; A.T. Shaw

doi:10.1016/j.lungcan.2019.10.015

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

S.H.I. Ou, S.M. Gadgeel, F. Barlesi, J.C.H. Yang, L. De Petris, D.W. Kim, R. Govindan, A.M. Dingemans, L. Crino, H. Lena, S. Popat, J.S. Ahn, E. Dansin, E. Mitry, B. Muller, W. Bordogna, B. Balas, P.N. Morcos, A.T. Shaw

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	22-27
Number of pages	6
Journal	Lung Cancer
Volume	139
DOIs	https://doi.org/10.1016/j.lungcan.2019.10.015
Publication status	Published - 1 Jan 2020

Keywords

alectinib
alk
crizotinib
nsclc
overall survival
pooled analysis
safety
ALK
NSCLC
Pooled analysis
Alectinib
CRIZOTINIB
Safety
Overall survival

Access to Document

10.1016/j.lungcan.2019.10.015

Cite this

Ou, S. H. I., Gadgeel, S. M., Barlesi, F., Yang, J. C. H., De Petris, L., Kim, D. W., Govindan, R., Dingemans, A. M., Crino, L., Lena, H., Popat, S., Ahn, J. S., Dansin, E., Mitry, E., Muller, B., Bordogna, W., Balas, B., Morcos, P. N., & Shaw, A. T. (2020). Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 139, 22-27. https://doi.org/10.1016/j.lungcan.2019.10.015

Ou, S.H.I. ; Gadgeel, S.M. ; Barlesi, F. ; Yang, J.C.H. ; De Petris, L. ; Kim, D.W. ; Govindan, R. ; Dingemans, A.M. ; Crino, L. ; Lena, H. ; Popat, S. ; Ahn, J.S. ; Dansin, E. ; Mitry, E. ; Muller, B. ; Bordogna, W. ; Balas, B. ; Morcos, P.N. ; Shaw, A.T. / Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. In: Lung Cancer. 2020 ; Vol. 139. pp. 22-27.

@article{d8c1a613867b4ca7b95ce1b49509a349,

title = "Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer",

keywords = "alectinib, alk, crizotinib, nsclc, overall survival, pooled analysis, safety, ALK, NSCLC, Pooled analysis, Alectinib, CRIZOTINIB, Safety, Overall survival",

author = "S.H.I. Ou and S.M. Gadgeel and F. Barlesi and J.C.H. Yang and {De Petris}, L. and D.W. Kim and R. Govindan and A.M. Dingemans and L. Crino and H. Lena and S. Popat and J.S. Ahn and E. Dansin and E. Mitry and B. Muller and W. Bordogna and B. Balas and P.N. Morcos and A.T. Shaw",

year = "2020",

month = jan,

day = "1",

doi = "10.1016/j.lungcan.2019.10.015",

language = "English",

volume = "139",

pages = "22--27",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Ou, SHI, Gadgeel, SM, Barlesi, F, Yang, JCH, De Petris, L, Kim, DW, Govindan, R, Dingemans, AM, Crino, L, Lena, H, Popat, S, Ahn, JS, Dansin, E, Mitry, E, Muller, B, Bordogna, W, Balas, B, Morcos, PN & Shaw, AT 2020, 'Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer', Lung Cancer, vol. 139, pp. 22-27. https://doi.org/10.1016/j.lungcan.2019.10.015

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. / Ou, S.H.I.; Gadgeel, S.M.; Barlesi, F.; Yang, J.C.H.; De Petris, L.; Kim, D.W.; Govindan, R.; Dingemans, A.M.; Crino, L.; Lena, H.; Popat, S.; Ahn, J.S.; Dansin, E.; Mitry, E.; Muller, B.; Bordogna, W.; Balas, B.; Morcos, P.N.; Shaw, A.T.

In: Lung Cancer, Vol. 139, 01.01.2020, p. 22-27.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

AU - Ou, S.H.I.

AU - Gadgeel, S.M.

AU - Barlesi, F.

AU - Yang, J.C.H.

AU - De Petris, L.

AU - Kim, D.W.

AU - Govindan, R.

AU - Dingemans, A.M.

AU - Crino, L.

AU - Lena, H.

AU - Popat, S.

AU - Ahn, J.S.

AU - Dansin, E.

AU - Mitry, E.

AU - Muller, B.

AU - Bordogna, W.

AU - Balas, B.

AU - Morcos, P.N.

AU - Shaw, A.T.

PY - 2020/1/1

Y1 - 2020/1/1

KW - alectinib

KW - alk

KW - crizotinib

KW - nsclc

KW - overall survival

KW - pooled analysis

KW - safety

KW - ALK

KW - NSCLC

KW - Pooled analysis

KW - Alectinib

KW - CRIZOTINIB

KW - Safety

KW - Overall survival

U2 - 10.1016/j.lungcan.2019.10.015

DO - 10.1016/j.lungcan.2019.10.015

M3 - Article

C2 - 31706099

VL - 139

SP - 22

EP - 27

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -